Back to Registry

Retatrutide

Also known as: LY-3437943

Phase III

Molecular Formula

C221 H342 N46 O68

Molecular Weight

4,731.34 Da

Half-Life

~6 days

Sequence

Y-{Aib}-QGTFTSDYSI-{α-Me-L}-LDKK((AEEA)-γ-Glu-C20 diacid)AQ-{Aib}-AFIEYLLEGGPSSGAPPPS-NH2

Clinical Applications & Evidence

Mechanism of Action

Retatrutide operates via synergistic triple agonism. GLP-1 and GIP receptor activation delays gastric emptying, signals central satiety, and stimulates glucose-dependent insulin release. Concurrent glucagon receptor activation promotes hepatic lipid oxidation and increases resting energy expenditure, uniquely driving thermogenesis to bypass the metabolic adaptation typically seen in mono- or dual-incretin therapies.

Investigated Uses

  • Obesity (up to 24% body weight reduction in Phase 2)
  • Type 2 Diabetes Mellitus
  • Non-alcoholic fatty liver disease (NAFLD/MASH)
  • Metabolic syndrome
  • Obstructive sleep apnea
  • Knee osteoarthritis
Moderate Clinical Data

Regulatory & Safety Status

FDA Status

Phase III

WADA / Athletic Status

Prohibited in Competition

Known Side Effects

NauseaDiarrheaVomitingDecreased appetiteConstipation

Contraindications

  • Thyroid C-cell tumors (preclinical signal)
  • Pancreatitis history

Drug Interactions

  • Insulin and sulfonylureas
  • Oral medications (altered absorption)

Citations & Clinical Trials

Eli Lilly Investor Relations Lilly's triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs... PubMed Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials ChemicalBook LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss